IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1051-1075 out of 1272.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

Public Release: 18-Jun-2014
Tobacco Control
Study shows cost-effectiveness of smoking cessation counseling during hospitalization
In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation, an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

Contact: Vincent Lamontagne
University of Ottawa Heart Institute

Public Release: 18-Jun-2014
Cancer Immunology Research
Vaccine 'reprograms' pancreatic cancers to respond to immunotherapy
Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.
NIH/National Cancer Institute

Contact: Michelle Potter
Johns Hopkins Medicine

Public Release: 18-Jun-2014
British Journal of Obstetrics and Gynaecology
No link found between soy food and endometrial cancer risk, say researchers
Researchers have found no evidence of a protective association between soy food and endometrial cancer risk, says a new study published June 18 in BJOG: An International Journal of Obstetrics and Gynaecology.

Contact: Nicole Weingartner

Public Release: 18-Jun-2014
JAMA Surgery
Racial disparities in sentinel lymph node biopsy in women with breast cancer
The use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity that contributed to disparities in the risk for lymphedema (arm swelling common after breast cancer treatment because of damage to the lymphatic system).

Contact: Julie A. Penne
The JAMA Network Journals

Public Release: 18-Jun-2014
New England Journal of Medicine
New report offers a primer for doctors' use of clinical genome and exome sequencing
Sooner than almost anyone expected, a new, genome-based technology for demystifying undiagnosed illnesses -- particularly rare childhood diseases -- is moving from research laboratories into general medical practice. Now, two leading scientists, writing in the June 19, 2014, issue of the New England Journal of Medicine, have sketched out what doctors need to know in order to use the new technology effectively.
National Institutes of Health

Contact: Raymond MacDougall
NIH/National Human Genome Research Institute

Public Release: 17-Jun-2014
Gut bacteria predict survival after stem cell transplant, study shows
New research published online today in Blood, the Journal of the American Society of Hematology, suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival.

Contact: Amanda Szabo
American Society of Hematology

Public Release: 17-Jun-2014
Study compares survival for treatments of uncommon eye cancer
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

Contact: Courtney DeNicola Nowak
The JAMA Network Journals

Public Release: 17-Jun-2014
TNF inhibitors for treatment of bowel disease not linked with increased risk of cancer
In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

Contact: Nynne Nyboe Andersen, M.D.
The JAMA Network Journals

Public Release: 17-Jun-2014
INFORMS Advances in Decision Analysis Conference
Breast cancer diagnosis, mammography improved by considering patient risk: INFORMS paper
A new approach to examining mammograms that takes into account a woman's health risk profile would reduce the number of cancer instances missed and also cut the number of false positives, according to a paper being presented at a conference of the Institute for Operations Research and the Management Sciences (INFORMS).

Contact: Barry List
Institute for Operations Research and the Management Sciences

Public Release: 17-Jun-2014
Journal of Clinical Investigation
Heparin derivative suppresses neuroblastoma tumor growth
Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming. The study, conducted in mice and published June 17, 2014, in the Journal of Clinical Investigation, found that when heparin is altered to remove its blood-thinning properties, it can suppress and shrink neuroblastoma tumors without causing severe bleeding.
National Institutes of Health, Alex's Lemonade Stand

Contact: Rachel Harrison
Duke University Medical Center

Public Release: 17-Jun-2014
Genetic pathway can slow spread of ovarian cancer
University of Adelaide research into the origins of ovarian cancer has led to the discovery of a genetic pathway that could slow the spread of the cancer.

Contact: Associate Professor Frank Grützner, University of Adelaide
University of Adelaide

Public Release: 17-Jun-2014
Breast Cancer Research and Treatment
Potential cholesterol lowering drug has breast cancer fighting capabilities
Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.
Department of Defense Breast Cancer Program

Contact: Jeff Sossamon
University of Missouri-Columbia

Public Release: 17-Jun-2014
American Journal of Roentgenology
3D breast imaging could revolutionize cancer screening
The largest report to date shows that 3D DBT (versus 2D DM) increases the detection rate for cancer overall by 28.6 percent and by 43.8 percent in detecting invasive cancers.

Contact: Lissa D. Hurwitz
American Roentgen Ray Society

Public Release: 17-Jun-2014
Tobacco Control
Want to know about vaping? Turn on the TV or go online
UIC study finds social networking is a critical component of e-cig marketing.

Contact: Sherri McGinnis Gonzalez
University of Illinois at Chicago

Public Release: 17-Jun-2014
Current Oncology
Barriers to obtaining gene expression profiling test heightened perceived value
Barriers to obtaining gene expression profiling tests heightened their perceived importance among patients with early breast cancer who were deciding whether to have chemotherapy, a new study says.
Cancer Care Ontario, Ontario Institute for Cancer Research, Canadian Centre for Applie

Contact: Leslie Shepherd
St. Michael's Hospital

Public Release: 17-Jun-2014
$2.4 million NIH center grant to develop a cleaner, healthier environment in Detroit
With over $2.4 million in new federal funding, Wayne State University researchers, regional collaborators at Henry Ford Health System, the University of Michigan and Michigan State University, and community partners will study how exposures to stressors that are prevalent in the urban industrialized environment -- both chemical and non-chemical -- impact human health in Detroit and beyond.
NIH/National Institute of Environmental Health Sciences

Contact: Julie O'Connor
Wayne State University - Office of the Vice President for Research

Public Release: 16-Jun-2014
Nature Materials
Tugging on the 'malignant' switch
A team of Harvard researchers have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast cancer.
National Institutes of Health, National Science Foundation, Natural Sciences and Engineering Research Council of Canada, Howard Hughes Medical Institute, and others

Contact: Caroline Perry
Harvard University

Public Release: 16-Jun-2014
Cancer Prevention Research
Broccoli sprout drink enhances detoxification of air pollutants in clinical trial in China
A clinical trial involving nearly 300 Chinese men and women residing in one of China's most polluted regions found that daily consumption of a half cup of broccoli sprout beverage produced rapid, significant and sustained higher levels of excretion of benzene, a known human carcinogen, and acrolein, a lung irritant.
National Institutes of Health

Contact: Susan Sperry
Johns Hopkins University Bloomberg School of Public Health

Public Release: 16-Jun-2014
Medical Care
Most prostate cancer specialists don't recommend active surveillance for low-risk patients
Specialists who treat prostate cancer agree that active surveillance is an effective option -- yet most don't recommend it when appropriate for their own patients, according to a study in the July issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Wolters Kluwer Health

Public Release: 16-Jun-2014
JAMA Internal Medicine
How to prevent disparities in colon cancer screening
People living in poverty are less likely to be screened for colorectal cancer -- and more likely to develop the disease and die from it. Mailing a stool test promises to help end these disparities, write Beverly Green, M.D., M.P.H., and Gloria Coronado, Ph.D., of Kaiser Permanente Center for Health Research in JAMA Internal Medicine.

Contact: Rebecca Hughes
Group Health Research Institute

Public Release: 16-Jun-2014
Genes & Development
Gene 'switch' reverses cancer in common childhood leukaemia
Melbourne researchers have shown a type of leukaemia can be successfully 'reversed' by coaxing the cancer cells back into normal development. The discovery was made using a model of B-progenitor acute lymphoblastic leukaemia, the most common cancer affecting children. Researchers from the Walter and Eliza Hall Institute showed that switching off a gene called Pax5 could cause cancer in a model of B-ALL, while restoring its function could 'cure' the disease.
National Health and Medical Research Council, Leukaemia Foundation, Sylvia and Charles Viertel Foundation, VESKI, Victorian Government

Contact: Liz Williams
Walter and Eliza Hall Institute

Public Release: 16-Jun-2014
Tobacco Control
E-cigs heavily marketed on Twitter, study finds
E-cigarettes, also known as vaping pens or e-hookas, are commonly advertised on Twitter and the tweets often link to commercial websites promoting e-cig use, according to University of Illinois at Chicago researchers.

Contact: Sherri McGinnis Gonzalez
University of Illinois at Chicago

Public Release: 16-Jun-2014
Nano Letters
Nanoshell shields foreign enzymes used to starve cancer cells from immune system
Nanoengineers at the University of California, San Diego have developed a nanoshell to protect foreign enzymes used to starve cancer cells as part of chemotherapy. Their work is featured on the June 2014 cover of the journal Nano Letters. Enzymes are naturally smart machines that are responsible for many complex functions and chemical reactions in biology. However, despite their huge potential, their use in medicine has been limited by the immune system, which is designed to attack foreign intruders.
National Cancer Institute

Contact: Catherine Hockmuth
University of California - San Diego

Public Release: 16-Jun-2014
Clinical Cancer Research
Low dose of targeted drug might improve cancer-killing virus therapy
Giving low doses of the targeted agent bortezomib with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer with little added toxicity. The findings support the testing of this combination therapy in a clinical trial.
National Institutes of Health, Ohio State University Pelotonia Fellowship Program

Contact: Darrell E. Ward
Ohio State University Wexner Medical Center

Public Release: 16-Jun-2014
Journal of Oncology Practice
When patients wish for a miracle, tool helps medical staff say 'amen'
Cancer clinicians and a chaplain at the Johns Hopkins Kimmel Cancer Center have developed a new tool to help doctors, nurses and other health-care providers talk to dying patients and families who are, literally, praying for a miracle.

Contact: Michelle Potter
Johns Hopkins Medicine

Showing releases 1051-1075 out of 1272.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

  Search News Releases